



**T1D Exchange QI Collaborative
Clinical Leadership Committee Charter**
Last Updated: April 12, 2024

Purpose

T1D Exchange QI Collaborative (“T1DX-QI”) established a Clinical Leadership Committee to provide expert consultation to the Quality Improvement initiatives, including advising clinical direction of the T1DX-QI overall, including goals, key QI metrics, and areas of focus.

Structure and Processes

A. Membership

See Clinical Leadership webpage for a list of current members and clinical representation.

The Committee consists of one clinical representative per center. Members will consist of PI endocrinologists/diabetologist/internist who are actively working for and committed to pediatric, adult, and older adult populations with diabetes.

Members will include:

- a T1D Exchange Quality Improvement Team
- b Nominated Committee co-chairs
- c Appointed PI center leads from each clinic

B. Leadership Co-Chairs

Co-chairs serve two-year terms to lead the T1DX-QI Clinical Leadership Committee. Whenever possible, the Committee will be led by one pediatric and one adult provider.

New co-chairs are identified through a peer- and self-nomination process and ideally are already existing members of the Committee. In the event no nominations are received, current co-chairs may outreach to potential candidates to encourage their nominations. If no existing members are nominated, or nominees are brand new to the Committee, retiring and newly appointed co-chairs may overlap terms to support Committee work and sustainability.

C. Meetings

The Committee will meet at least quarterly. In-person meetings will be scheduled-ad hoc, depending on the workflow and member consensus.

C. Responsibilities and Duties

The following functions are expected to be the common recurring activities of the Committee in carrying out its responsibilities. These functions should serve as a guide with the understanding that the Committee may carry out additional functions and set priorities and procedures.

The Committee will help inform the strategic direction, study or intervention design, dissemination design and assist in identifying new opportunities for T1D Exchange and contribute to the understanding, treatment and other solutions effecting diabetes. The group will set and review priorities; these discussions will result in actionable recommendations for the direction of the T1DX-QI. The Committee advises and supports the identification of external collaborations and potential funding opportunities for T1D Exchange, as needed.

To support these activities:

Committee co-chairs will:

- Contribute to the long-term vision of Committee goals and deliverables
- Facilitate conversations with Committee members on QI/research projects and exploring potential partnership opportunities
- Develop meeting agendas

Committee members will:

- Attend quarterly meetings
- Provide feedback on current and future project proposals
- Support the research and QI focus of the collaborative by promoting opportunities for potential sponsored partnerships

T1DX team members will:

- Support with meeting scheduling, logistics, minutes, and recordings
- Maintain the Clinical Leadership Committee [website](#) with up-to-date information and documentation

D. Conflicts of Interest Committee members must abide by T1D Exchange’s duality/conflict of interest policy. They are requested to disclose all financial interests and working relationships with any entity whose financial interests potentially could be affected by the conduct or outcome of T1D Exchange activities; including all relationships that might have a bearing on his/her role or the perception of this role.

E. Confidentiality

Committee members will keep the material reviewed and deliberations of the Committee strictly confidential. If a Committee member has uncertainty about whether an issue or materials should be kept confidential, this should be discussed with the Chief Medical Officer of T1D Exchange Inc.